| 2012-03 |
CYP1A2 genetic polymorphisms associated with antidepressant escitalopram metabolism and adverse reactions at early stage |
Clinical Pharmacology and Therapeutics. 2012 Mar;91(Suppl. 1):S62. |
 |
| 2012-03 |
Genome-wide association study of treatment refractory schizophrenia in Han Chinese |
PLoS ONE. 2012 Mar;7(3):Article number e33598. |
|
| 2011-12 |
Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia |
Journal of Clinical Psychopharmacology. 2011 Dec;31(6):758-762. |
|
| 2011-10 |
Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients |
Pharmacogenomics. 2011 Oct;12(10):1397-1406. |
|
| 2011-08 |
CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer |
Journal of Clinical Psychopharmacology. 2011 Aug;31(4):463-469. |
|
| 2011-06 |
ANXA7, PPP3CB, DNAJC9, and ZMYND17 Genes at chromosome 10q22 associated with the subgroup of schizophrenia with deficits in attention and executive function |
Biological Psychiatry. 2011 Jul;70(1):51-58. |
|
| 2011-05 |
Genetic polymorphisms in PXR associated with serum concentration and metabolism to treatment with the antidepressant paroxetine |
Drug Metabolism Reviews. 2011 May;43(Suppl.1):71. |
|
| 2011-05 |
The genetic polymorphisms in ALDH2 influence the methadone dose and adverse reactions in patients with heroin addiction |
Drug Metabolism Reviews. 2011 May;43(Suppl.1):26. |
|
| 2011-05 |
Genetic polymorphisms of CYP2C19 associated with the side effect and serum concentrations of antidepressant paroxetine |
Drug Metabolism Reviews. 2011 May;43(Suppl.1):25-26. |
|
| 2011-05 |
CACNG2 is associated with delusion-hallucination symptom dimension of schizophrenia, but not with clozapine treatment outcome |
Biological Psychiatry. 2011 May;69(9 Suppl. 1):281S. |
|
| 2011-05 |
Opioid receptor Mu1 genetic polymorphisms influence QT prolongation and insomnia in methadone maintenance patients |
Biological Psychiatry. 2011 May;69(9 Suppl.1):229S-230S. |
|
| 2011-04 |
ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment |
Pharmacogenetics and Genomics. 2011 Apr;21(4):163-170. |
|
| 2010-11 |
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine |
Pharmacogenomics. 2010 Nov;11(11):1535-1543. |
|
| 2010-07 |
Development of a method to measure methadone enantiomers and its metabolites without enantiomer standard compounds for the plasma of methadone maintenance patients |
Biomedical Chromatography. 2010 Jul;24(7):782-788. |
|
| 2010-05 |
Good responders have higher plasma concentrations of aripiprazole in patients with schizophrenia |
International Journal of Neuropsychopharmacology. 2010 May;13(Suppl. S1):204. |
|
| 2010-04 |
Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response |
Pharmacogenomics. 2010 Apr;11(4):537-546. |
|
| 2010-01-14 |
Genetic variants of IL-6 and its receptor are not associated with schizophrenia in Taiwan |
Neuroscience Letters. 2010 Jan 14;468(3):330-333. |
|
| 2009-11 |
Clustering by neurocognition for fine mapping of the schizophrenia susceptibility loci on chromosome 6p |
Genes, Brain and Behavior. 2009 Nov;8(8):785-794. |
|
| 2009-10 |
Cytochrome P-450 Isozyme 2C19 Genetic Polymorphisms are Associated with Plasma Concentrations of Escitalopram |
Therapeutic Drug Monitoring. 2009 Oct;31(5):166. |
|
| 2009-07 |
Construction of Balanced Translocation t(1;11)(q42.1;q14.3) Probe and Screening Application in Genomic Samples in Taiwan |
Journal of the Formosan Medical Association. 2009 Jul;108(7):587-591. |
|
| 2009-04 |
Association of the 3'region of COMT with Schizophrenia in Taiwan |
Journal of the Formosan Medical Association. 2009 Apr;108(4):301-309. |
|
| 2008-12-12 |
A protein interaction based model for schizophrenia study |
BMC Bioinformatics. 2008 Dec 12;9(Suppl. 12):Article number S23. |
|
| 2008-11 |
RASD2, MYH9, and CACNG2 Genes at Chromosome 22q12 Associated with the Subgroup of Schizophrenia with Non-Deficit in Sustained Attention and Executive Function |
Biological Psychiatry. 2008 Nov;64(9):789-796. |
|
| 2007-12 |
HTF9C gene of 22q11.21 region associates with schizophrenia having deficit-sustained attention |
Psychiatric Genetics. 2007 Dec;17(6):333-338. |
|
| 2007-10 |
More evidence supports the association of PPP3CC with schizophrenia |
Molecular Psychiatry. 2007 Oct;12(10):966-974. |
|
| 2007-07 |
No association evidence between schizophrenia and dystrobrevin-binding protein 1 (DTNBP1) in Taiwanese families |
Schizophrenia Research. 2007 Jul;93(1-3):391-398. |
|
| 2006-10 |
No association of G72 and D-amino acid oxidase genes with schizophrenia |
Schizophrenia Research. 2006 Oct;87(1-3):15-20. |
|
| 2006-10 |
Systematic mutation screening study for DISC1 and NRG1 in schizophrenia |
American Journal of Medical Genetics Part B-Neuropsychiatric Genetics. 2006 Oct;141B(7):794. |
|
| 2006-10 |
Systematic SNP polymorphism screening for schizophrenia candidate gene of calcium channel, voltage-dependent, gamma subunit (CACNG2) |
American Journal of Medical Genetics Part B-Neuropsychiatric Genetics. 2006 Oct;141B(7):802. |
|
| 2006-09-15 |
A single nucleotide polymorphism fine mapping study of chromosome 1q42.1 reveals the vulnerability genes for schizophrenia, GNPAT and DISC1: Association with impairment of sustained attention |
Biological Psychiatry. 2006 Sep;60(6):554-562. |
|
